Zacks Investment Management Acquires New Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Zacks Investment Management bought a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,340 shares of the company’s stock, valued at approximately $68,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ZNTL. Walleye Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $587,000. Barclays PLC lifted its stake in Zentalis Pharmaceuticals by 55.7% in the fourth quarter. Barclays PLC now owns 117,395 shares of the company’s stock valued at $355,000 after buying an additional 42,000 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at $68,000. Cerity Partners LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $40,000. Finally, Federated Hermes Inc. grew its position in shares of Zentalis Pharmaceuticals by 2.2% during the fourth quarter. Federated Hermes Inc. now owns 493,982 shares of the company’s stock worth $1,497,000 after acquiring an additional 10,644 shares during the last quarter.

Zentalis Pharmaceuticals Stock Up 2.4 %

NASDAQ:ZNTL opened at $1.29 on Monday. The business’s 50-day moving average price is $1.76 and its 200 day moving average price is $2.56. Zentalis Pharmaceuticals, Inc. has a 52-week low of $1.01 and a 52-week high of $13.46. The firm has a market cap of $92.64 million, a P/E ratio of -0.52 and a beta of 1.80.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. Sell-side analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, Director Jan Skvarka bought 60,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ingmar Bruns purchased 20,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. This represents a 120.27 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ZNTL has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company cut their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.